TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Polidocanol Foam Versus Rubber Band Ligation in the Treatment of Hemorrhoidal Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients referred to proctologic consultation of Centro Hospitalar Universitário do Porto (CHUP) older than 18 years;~* Clinical diagnosis of hemorrhoidal disease grade I, II and III (Goligher's classification);~* Refractory to conservative management (dietary modification, intestinal transit modifiers, topical and phlebotonic medications) for a period of no less than 4 weeks.~Exclusion Criteria:~* Hepatic cirrhosis;~* Pregnant or breast-feeding women;~* Known allergy to polidocanol~* Another perianal disease that can cause symptoms similar to hemorrhoidal disease;~* Concomitant presence of external hemorrhoidal disease and/or hemorrhoidal thrombosis;~* Office-based or surgical treatment for hemorrhoids within 6 months prior to inclusion;~* Antiplatelet or hypocoagulant medication;~* Inherited bleeding disorders;~* Immunosuppressive states ;~* Inflammatory bowel disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Polidocanol foam sclerotherapy (Type: EXPERIMENTAL): 1. Preparation of the polidocanol foam according to Tessari technique immediately before application (so that the microbubbles of the foam did not disintegrate);~2. Application according to the Blanchard technique (Fig. 2) through a disposable transparent anoscope, with the patient in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle;~3. Patients treated in a maximum of 3 sessions at 3 weeks intervals;~4. Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air;~5. In each session more than one hemorrhoid cushion could be treated.
- Rubber band ligation (Type: EXPERIMENTAL): 1. Use of reusable metal ligation device connected to a vacuum system (McGown suction method) to apply the rubber bands above the dentated line through a disposable transparent anoscope with the patient in jackknife position;~2. A maximum of 3 sessions of ligation at 3-week intervals were performed;~3. More than 1 band per session could be applied.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Postoperative Wound Infections by Antiseptica?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - planned laparotomy for visceral surgery~Exclusion Criteria:~* Age under 18 years~* allergy against polihexanid~* laparoscopic surgery~* emergency surgery~* lack of understanding of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subcutaneous irrigation with 0.04% polyhexanide solution (Type: EXPERIMENTAL): Intervention: after closure of abdominal fascia, an intraoperative irrigation of the subcutaneous tissue with 250 ml antiseptic solution (0.04% polyhexanide) will be done once for ten minutes.~No subcutaneous suture. Closure of skin with either staples, interrupted sutures or running suture.
- Subcutaneous irrigation with NaCl (saline) (Type: ACTIVE_COMPARATOR): Intervention: after closure of fascia, an intraoperative irrigation of the subcutaneous tissue with 250 ml NaCl (saline) will be done once for one minute.~No subcutaneous suture. Closure of skin with either staples, interrupted sutures or running suture.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Type 1 or Type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) ≤ 12.0%~* Patients with visual impairment due to DME in at least one eye~* BCVA ≥ 24 and ≤ 78 letters in the study eye~Exclusion Criteria:~* Active intraocular inflammation~* Any active infection in either eye at the~* Structural damage within 0.5 disc diameter of the center of the macula in the study eye~* Uncontrolled glaucoma in either eye at screening~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Discretion of the investigator (DI) (Type: EXPERIMENTAL): ranibizumab 0.5 mg, after initial monthly treatment until maximum BCVA and no signs or no further change of disease activity, the investigator treated patients at their own discretion. There were no strict recommendations for retreatment or scheduling of upcoming visits.
- Pro re nata (PRN) (Type: ACTIVE_COMPARATOR): ranibizumab 0.5 mg, after initial monthly therapy until maximum BCVA and no signs or no further improvement of disease activity, patients were monitored every month and retreated if any signs of disease activity occurred

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab Effect iN pOlymyalgia Rheumatica

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 50 years and 75 years included~* PMR-AS \> 10~* PMR according to the Chuang criteria~* Evolving since less than 12 months~* Without Horton disease~* Able to understand and accept the study~* Agree to sign the inform consent form~* Without GC, or at least during 1 month and stop since 7 days before the inclusion.~* Stable dose of Nonsteroidal anti-inflammatory since 4 weeks before the inclusion.~* Birth controlled during all the study and 6 months after~Exclusion Criteria:~* Disagree to participated~* Unable to understand the study~* Participation to an other study in the 3 months before the inclusion~* Treated by GC at 0.3mg/kg/d in the past 7 days~* Less than 50 years old or more than 75 years old~* Uncontrolled dyslipidemia, high blood pressure or cardiovascular disease~* Histories of important allergy~* Historically positive test or test positive at screening for HIV-1 antibody, hepatitis B surface antigen, or hepatitis C antibody.~* Abnormal screening blood test : leukocyte count less than 3.5 × 109 cells/L, neutrophil count less than 2 × 109 cells/L, hemoglobin level less than 85 g/L, platelet count less than 100 × 109 cells/L, or hepatic aminotransferase or alkaline phosphatase levels greater than 3 times the upper limit of normal~* Other inflammatory rheumatic disease or connective disease~* Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to PMR (eg. Cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy or infectious diseases)~* Current drug or alcohol abuse~* Patients treated with an immunosuppressive agents in the past 4 weeks~* Live/attenuated vaccine in the past 4 weeks~* Clinical symptoms of giant cell arteritis~* History of infection or infestation in the past 3 months~* Active tuberculosis~* Planned surgical procedure~* History of malignant neoplasm within the last 5 years, except for adequately treated cancer of the skin (basal or squamous cell)~* History or current tumoral hematological disease~* Severe allergic or anaphylactic reactions about one of the TCZ component~* Pregnant women during the study and six month after the end of the study~* Breast feeding mother~* Dysthyroidia~* Unstable treatment by statin in the past 3 months~* Parkinson disease~* Fibromyalgia~* Peripheric arthritis~* Articular chondrocalcinosis or hydorxyapatites rhumatisms

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TCZ (Type: EXPERIMENTAL): Tocilizumab at week 0, week 4 and week 8 8mg/kg at each perfusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Noninvasive, Subharmonic Intra-Cardiac Pressure Measurement

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be scheduled for a cardiac catheterization procedure~* Adult patients over the age of 21~* Acceptable baseline echocardiographic images in the supine position~* If a female of child-bearing potential, must have a negative pregnancy test~* Provide written informed consent~Exclusion Criteria:~* Clinically unstable patients, e.g., those who are clinically in decompensated heart failure or having active chest pain or presenting for admission with an unstable anginal syndrome~* Patients in whom introduction of a catheter into the left ventricle is contraindicated or would potentially be dangerous, e.g., patients with active ventricular arrhythmias or with significant aortic valve stenosis where crossing the aortic valve may be difficult and not clinically necessary~* Patients with anatomic right-to-left, bi-directional, or transient right-to-left cardiac shunts where Definity could traverse as a bolus~* Patients with known hypersensitivity to Definity~* Females who are pregnant or nursing

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Definity for pressure measurements (Type: EXPERIMENTAL): 2 vials of activated Definity mixed with 50 ml saline. As per manufacturer's recommendation the infusion rate may vary between 4-10 ml/min (to provide diagnostic intracardiac contrast visibility).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing surgical extraction of a single fully or partially impacted mandibular 3rd molar requiring bone removal.~* Patients experiencing moderate to severe post-operative pain within 6 hours from end of surgery.~* Pre-operative laboratory tests in the reference ranges or without clinically significant abnormalities as judged by the Investigator.~Exclusion Criteria:~* Surgery performed under general anaesthesia, or sedation.~* Complications occurring during the surgical procedure or in the period before randomisation as judged by the investigator.~* Acute local or systemic infection at the time of surgery that could confound the post-surgical evaluation.~* Patients with clinical signs of gastritis, gastro-duodenal ulcer, GI bleeding. Other GI disturbances or disease that in the opinion of the investigator could be negatively affected by the administration of NSAIDs.~* Clinical signs or history of coagulation disorders that could be negatively affected by NSAIDs administration.~* Hepatic or renal impairment.~* Patients with significant cardiac impairment, history of cerebrovascular disease, history or peripheral arterial disease, uncontrolled hypertension.~* Hypersensitivity to diclofenac or other NSAIDs or to one of the study medication components.~* Patients under chronic treatment with topical or systemic analgesics/NSAIDs.~* Patients under treatment with any medication that may affect the treatment efficacy evaluation.~* Patients under treatment with any medication whose concomitant use may be susceptible to interactions with diclofenac or may affect safety.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Diclofenac HPBCD s.c. 25mg/ml (Type: EXPERIMENTAL): None
- Diclofenac HPBCD s.c. 50mg/ml (Type: EXPERIMENTAL): None
- Diclofenac HPBCD s.c. 75mg/ml (Type: ACTIVE_COMPARATOR): None
- Placebo s.c. (1ml) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
OLE Period Key Inclusion Criteria:~* Successful completion of clinical study C601~* Provide voluntary, written informed consent (parent(s) / legal guardian(s) of patient); provide voluntary, written assent (subjects, as appropriate)~OLE Period Key Exclusion Criteria:~* Positive urine pregnancy test (in females of child-bearing potential) or females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 90 days after study participation~* Any new disease, condition, or circumstance which would prevent, in the opinion of the Investigator, the patient from completing all study visits and assessments required by the protocol (e.g., an anticipated change of care setting)~RW Period Key Inclusion Criteria:~* Provide voluntary, written informed consent (parent\[s\] / legal guardian\[s\] of participant); provide voluntary, written assent (participants, as appropriate); this includes consent for randomization and potential treatment with placebo for up to 16 weeks~* Currently participating in clinical study C602 and complete the OLE End of Treatment Visit procedures~RW Period Key Exclusion Criteria:~* Positive urine pregnancy test (in females of child-bearing potential)~* Females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 30 days after study participation

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OLE DCCR (Type: EXPERIMENTAL): 75 - 525 mg DCCR
- RW DCCR (Type: EXPERIMENTAL): 75 - 525 mg DCCR
- RW Placebo (Type: PLACEBO_COMPARATOR): 75 - 525 mg Placebo for DCCR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent form~* Male or female of aged 50 years or older~* Typical AMD and PCV patients~* BCVA of 24 letters or over~Exclusion Criteria:~* Total lesion area of \>12 DA or \>30.5 mm2~* The existence of subretinal hemorrhage area constituting ≥50% of total lesion area~* The existence of scar or fibrosis area constituting ≥50% of total lesion area~* The existence of RPE tear~* Prior treatment for wet AMD~* History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD~* The pregnant or lactating woman

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intraviteal Ranibizumab 0.5mg (Type: EXPERIMENTAL): Intraviteal Ranibizumab 0.5mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female age 18 to 75 years of age (inclusive) at the time of screening.~* Females of childbearing potential, defined as a female who is fertile following menarche, must have a negative serum pregnancy test at screening and agree to use an acceptable method of contraception throughout their participation in the study.~Note: Female subjects who have been surgically sterilized (e.g., hysterectomy or bilateral tubal ligation) or who are postmenopausal (defined as total cessation of menses for \> 1 year) will not be considered female subjects of childbearing potential.~* Subject is hospitalized with liver cirrhosis and/or OHE and has a confirmed diagnosis of OHE at Baseline.~* Subject has a Grade 2 or Grade 3 HE episode according to the HE Grading Instrument (HEGI) following 8 to 12 hours of intravenous (IV) hydration and lactulose treatment.~Exclusion Criteria:~* Subject has an uncontrolled major psychiatric disorder including major depression or psychoses as determined by the investigator.~* Subject has been diagnosed with an infection for which they are currently taking oral or parenteral antibiotics, which cannot be discontinued at time of enrollment. Note: Subjects currently taking Rifaximin are not excluded~* Subject shows presence of intestinal obstruction or has inflammatory bowel disease.~* Subject has uncontrolled Type 1 or Type 2 diabetes. Note: Subjects with controlled diabetes may be enrolled if they are on stable doses of oral hypoglycemic drugs for at least 3 months prior to screening, and demonstrate clinically acceptable blood glucose control at Baseline, as determined by the investigator.~* Subject has an active malignancy (exceptions: non-melanoma skin cancers).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 40 mg Rifaximin SSD once daily (Type: EXPERIMENTAL): 40 mg Rifaximin immediate release (IR) rifaximin SSD once daily (QD) and lactulose
- Cohort 2 40 mg Rifaximin SSD twice daily (Type: EXPERIMENTAL): 40 mg Rifaximin immediate release (IR) rifaximin SSD twice daily (BID) and lactulose
- Cohort 3 80 mg Rifaximin SSD once daily (Type: EXPERIMENTAL): 80 mg Rifaximin sustained extended release (SER) rifaximin SSD once daily (QD) and lactulose
- Cohort 4 80 mg Rifaximin SSD twice daiy (Type: EXPERIMENTAL): 80 mg Rifaximin sustained extended release (SER) rifaximin SSD twice daily (BID) and lactulose
- Cohort 5 Placebo twice daily (Type: EXPERIMENTAL): SSD placebo twice daily (BID) and lactulose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient must provide written, informed consent, and be ≥ 19 yrs of age.~* The patient is already receiving Fabrazyme® at 1 mg/kg every two weeks at the time of enrollment.~* Patient has confirmed Fabry disease (plasma αGAL activity of \< 1.5 nmol/hr/mL, or leukocyte αGAL activity of \< 4 nmol/hr/mg), or a known mutation compatible with Fabry disease.~* Patients with either:~  1. eGFRMDRD ≥ 20 and ≤ 60 ml/min/1.73 m2, and documented baseline urine protein/creatinine ratio \> 0.5, based on the last value obtained before initiating ACEI/ARB therapy or obtained at screening before the first Evaluation Visit of the FAACET Study; or~ 2. eGFRMDRD ≤ 125 ml/min/1.73 m2 and \> 60 ml/min/1.73 m2 with documented baseline urine protein/creatinine ratio \> 1, based on the last value obtained before initiating ACEI/ARB therapy or obtained at screening before the first Evaluation Visit of the FAACET Study.~Exclusion Criteria:~* The patient has undergone kidney transplantation or is currently on dialysis, or is planning on receiving a kidney transplant during the first year of the study.~* The patient has diabetic nephropathy or the presence of another, confounding kidney disease unless there is kidney biopsy confirmation that the patient does not have diabetic nephropathy or another, confounding kidney disease.~* The patient has a clinically significant organic disease, or other condition that in the opinion of the investigator would preclude participation in the full extent of the trial.~* The patient is unwilling to comply with the requirements of the protocol, including continuing on Fabrazyme® at 1 mg/kg body weight every two weeks.~* Patients who have documented allergies to ACE inhibitors and to ARBs are not eligible to participate in the FAACET Study.~* The patient is pregnant or intends to become pregnant during the course of the study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of Asthma~* Reversibility ≥ 12% and ≥200mls reversibility of FEV1 within approximately 30-minutes following 2 to 4 puffs of albuterol~* FEV1 between 40-85% predicted~* Currently on short acting beta2 agonist therapy~Key Exclusion Criteria:~* History of life threatening asthma~* Respiratory Infection or oropharyngeal candidiasis~* Asthma exacerbation~* Uncontrolled disease or clinical abnormality~* Allergies~* Taking another Investigational medications or other prohibited medications

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GW685698X (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete